このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Novonesis 配当金

配当金基準チェック /26

Novozymes配当を支払う会社であり、現在の利回りは1.34%です。

主要情報

0.8%

配当利回り

108%

配当性向

業界平均利回り	1.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	US$4.000
一株当たり利益	US$0.61
配当利回り予想	1.5%

最近の配当金アップデート

Recent updates

決済の安定と成長

配当データの取得

安定した配当: NVZM.Fの配当金支払いは、過去10年間変動性が高かった。

増加する配当: NVZM.Fの配当金は過去10年間にわたって増加しています。

配当利回り対市場

Novonesis 配当利回り対市場

NVZM.F 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (NVZM.F)	0.8%
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Chemicals)	1.8%
アナリスト予想 (NVZM.F) (最長3年)	1.5%

注目すべき配当: NVZM.Fの配当金 ( 1.47% ) はUS市場の配当金支払者の下位 25% ( 1.51% ) と比べると目立ったものではありません。

高配当: NVZM.Fの配当金 ( 1.44% ) はUS市場の配当金支払者の上位 25% ( 4.81% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: NVZM.Fは高い配当性向 ( 107.6% ) のため、配当金の支払いは利益によって十分にカバーされていません。

株主配当金

キャッシュフローカバレッジ: NVZM.Fの現金配当性向 ( 41.6% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。

Novonesis 配当金

配当金 基準チェック /26

主要情報

最近の配当金アップデート

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /26